<DOC>
	<DOCNO>NCT02084121</DOCNO>
	<brief_summary>A subject treat compassionate use provision study facilitate cell therapy ( FCRx ) product manufacture use CliniMACS ( Miltenyi Biotec ) device , rather Max Sep ( Baxter ) device .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Treatment Multiple Sclerosis ( Compassionate Use )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<criteria>1 . Patients must confirm diagnosis inherit metabolic disorder / inborn error metabolism . Diagnosis confirm appropriate test ( ) ( enzyme and/or mutation analysis ) study entry . Patients must eligible myeloablative chemotherapy preparative regimen transplant due age , comorbidities organ dysfunction . Inborn error metabolism / Inherited Metabolic Disorders ( IMD ) eligible Compassionate Use Provision include Metachromatic Leukodystrophy ( MLD ) 2 . Patients must ≥ 3 year age 3 . Patients must Lansky Karnofsky performance status ≥40 4 . Patients must adequate function organ system measure : Creatinine &lt; 2.0 mg/dl creatinine clearance ≥60 cc/min/1.73m2 . Newborns must creatinine clearance &gt; 25 cc/min . For baby &lt; 3 month age , raw value glomerular filtration rate ( GFR ) must &gt; 1 cc/kg/min . Hepatic transaminase ( ALT/AST ) ≤4 x normal , bilirubin &lt; 2.0mg/dl Normal cardiac function echocardiogram radionuclide scan ( ejection fraction shorten fraction &gt; 80 % normal value age ) Pulmonary function test demonstrate forced expiratory volume one second ( FEV1 ) &gt; 50 % predicted age . If child young pulmonary function test ( PFTs ) , cry vital capacity result &gt; 50 % normal value age rest pulse oximeter &gt; 85 % room air clearance pulmonologist require . 5 . Patient must relate donor [ identical mismatch 1 , 2 3 histocompatibility leukocyte antigen ( HLA ) A , B DR locus ] . 6 . Patient , parent , legal guardian must give write informed consent accord FDA guideline . 7 . Patients must minimum life expectancy least 6 month . 8 . Female patient childbearing potential pregnant lactating/breastfeeding must either surgically sterile , postmenopausal ( menses previous 12 month ) , must practice effective method birth control determine investigator ( e.g. , oral contraceptive , double barrier method , hormonal injectable implanted contraceptive , tubal ligation , partner vasectomy ) . Patients uncontrolled seizure , apnea , evidence recurrent uncontrolled aspiration , need chronic mechanical ventilation . Patients allogeneic stem cell transplant cytoreductive therapy past 6 month . Subjects must previous radiation therapy would preclude total body irradiation ( TBI ) ( determine radiation therapist ) Uncontrolled infection severe concomitant disease , judgment Principal Investigator , could tolerate reduce intensity transplantation . Severe impairment functional performance evidence Karnofsky ( patient &gt; 16 year old ) Lansky ( child &lt; 16 year old ) score &lt; 40 % Subjects positive human immunodeficiency virus ( HIV ) antibody test result Subjects pregnant , indicate positive serum human chorionic gonadotropin ( HCG ) test Subjects whose donor pregnant time intend transplant Subjects childbearing potential practicing adequate contraception define investigator site Jehovah 's witness Patients comorbid condition , view Principal Investigators , render patient high risk treatment complication regimen related morbidity/mortality . Lack related donor</criteria>
	<gender>Male</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metachromatic leukodystrophy</keyword>
</DOC>